

LIFECARE ASA: UPDATED KEY INFORMATION RELATING TO THE PREFERENTIAL RIGHTS ISSUE

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement published by Lifecare ASA (the "**Company**") on 25 April 2024 with key information relating to the preferential rights issue in the Company (the "**Rights Issue**"). Please see updated key information relating to the Rights Issue included below.

Date on which the terms and conditions of the Rights Issue were announced: 25 April 2024

Last day including right: 16 May 2024

Ex-date: 21 May 2024

Record Date: 22 May 2024

Date of approval: 16 May 2024

Maximum number of New Shares: 59,038,955

Subscription price: NOK 1.52442

Ratio preferential rights: Each existing shareholder as of 16 May 2024 (and being registered as such in Euronext Securities Oslo, the Norwegian Central Securities Depository, (the VPS) as at the expiry of 22 May 2024 (the record date)) will be granted 0.437760 subscription rights for each share registered as held by the shareholder. The number of subscription rights granted to each existing shareholder will be rounded down to the nearest whole subscription right.

Subscription ratio: 1:1 (number of new shares per subscription right)

Manager: Carnegie AS

Will the rights be listed: The Company will apply for trading of the Subscription Rights on Euronext Growth Oslo

ISIN for the preferential rights: To be announced when clarified

Other information: The subscribers in the Rights Issue will without cost be allocated one warrant issued by the Company for every two new shares allocated to, and paid by, them in the Rights Issue. The number of warrants to be issued will be minimum 24,599,564 and maximum 29,519,478. Each warrant will give the holder a right to subscribe for one new share in the Company at a subscription price equal to the volume-weighted average price (VWAP) of the Company's shares on Euronext Growth Oslo on the three last trading days prior to the first date on which the holder can exercise the warrant in each exercise period less 30%, but in any event not exceeding NOK 1.98174 (the subscription price in the Rights Issue plus 30%). The Warrants may be exercised in the exercise period from 2 June 2025 to 13 June 2025.

The Rights Issue is subject to approval by the Extraordinary General Meeting to be held on 16 May 2024.

Disclosure regulation

This information is published in accordance with the requirements of the Continuing Obligations for issuers listed on Euronext Growth Oslo.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("**NTR**") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare ASA, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no, +47 41 61 42 52